An influenza vaccine constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
A new course offered in the Biomedical Enterprise master’s program in the Institute for Biomedical Sciences teaches students about scientific commercialization.
A medicinal chemist, Wang is focused on tackling pressing health issues, including cancer, inflammation, antibiotic resistance and rare diseases.
In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate that has potent antiviral activity against SARS-CoV-2 when administered orally once-daily.
To better reach outpatients early after a COVID-19, infection, Gilead Sciences Inc. has partnered with researchers in Georgia State University’s Center for Translational Antiviral Research to test a modified version of remdesivir that can be taken orally.
A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.
Professor Christopher Basler has spent his career stalking Ebola, and recently he hit upon a surprising discovery that could suggest new ways to treat the deadly infection.
A new cancer treatment co-developed by associate professor Maged Henary is one of the first Georgia State-based technologies to enter clinical trials.
A new antiviral drug tested in the Institute for Biomedical Sciences at Georgia State against influenza virus and SARS-CoV-2 has been recommended for emergency use authorization to treat COVID-19 in the United States by pharmaceutical companies that completed a Phase 3 clinical trial and achieved promising results.
Professor Christopher Basler has received two grants from the National Institutes of Health to study two coronaviruses that cause human disease: Middle East respiratory syndrome (MERS) coronavirus and SARS-CoV-2.
